Amended Current Report Filing (8-k/a)
23 August 2022 - 6:19AM
Edgar (US Regulatory)
0001322505
false
0001322505
2022-08-08
2022-08-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 8, 2022
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in its
charter)
Delaware
(State or other jurisdiction of
incorporation) |
|
001-33451
(Commission File
Number) |
|
90-0136863
(IRS Employer
Identification No.) |
53 State Street, 19th Floor
Boston, Massachusetts
(Address of principal executive offices) |
|
02109
(Zip Code) |
(857) 254-5555
Registrant’s telephone number, including
area code
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock |
|
ALBO |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As previously
reported on the Current Report on Form 8-K (the “Original Filing”) filed by Albireo Pharma, Inc. (the
“Company”) on August 8, 2022, the Company’s Board of Directors (the “Board”) elected Susan Alesina
and Habib Dable as directors of the Company, effective as of August 8, 2022.
At the time
of the Original Filing, the Board had not made a determination regarding any committee assignments for Ms. Alesina or Mr. Dable. This
amended Current Report on Form 8-K is being filed to provide the committee assignment information omitted from the Original Filing. On
August 19, 2022, the Board appointed Ms. Alesina to the Audit Committee of the Board and appointed Mr. Dable to the Compensation Committee
of the Board, effective immediately.
Other than
the preceding disclosure, no other disclosure reported in the Original Filing is amended pursuant to this Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALBIREO PHARMA, INC. |
|
|
Date: August 22, 2022 |
/s/ Ronald H.W. Cooper |
|
Ronald H.W. Cooper |
|
President and Chief Executive Officer |
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2024 to May 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From May 2023 to May 2024